UDCAUrsodeoxycholic acidprogrammed cell death protein 1 inhibitorsChILICPI-induced cholangiopathyimmunosuppression regimens
…longed. Response to immunosuppression is limited and initiating UDCA can be considered in all patients.…
28articles mentioning drugs
75drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: UDCA ×
UDCA
This drug is selected. Its supporting articles are shown below.
Articles mentioning UDCA
28 articles · page 2 of 3BezafibrateObeticholic acidUrsodeoxycholic acidSeladelparElafibranorUDCAPrimary Biliary CholangitisPBC
…py, while 27% were prescribed second-line treatments, including Bezafibrate (31 patients), Obeticholic acid (20 patients), and Elafibranor …
OCA-FIBfibrateUDCAObeticholic acidFIB-OCAbezafibrateOCAprimary biliary cholangitisPBC
…le therapies Fibrate therapy First (FIB-OCA) OCA therapy First (OCA-FIB) (FIB-OCA) and (OCA-FIB) Comparative p Values ALP M0 (n27) M6 (…
ursodeoxycholic acidazathioprineUDCAcorticosteroidsSjögren’s syndromesystemic sclerosisautoimmune thyroiditispernicious anemiaautoimmune hepatitisimmunosuppressive therapy+4 more
…r histological).All patients were treated with a combination of ursodeoxycholic acid (UDCA) and immunosuppressive therapy (corticosteroids with or w…
Obeticholic acidbezafibrateursodeoxycholic acidUDCAprimary biliary cholangitisOffice for National StatisticsSLTThe Royal London Hospital hub centreUK tertiary hepatology centre
…43%) and Caucasian (39%) patients than in Asian patients (26%). Obeticholic acid was more widely prescribed than bezafibrate in all groups. Asia…
Ursodeoxycholic acid (UDCA)Obeticholic AcidObeticholic Acid (OCA)UDCAPrimary Biliary Cholangitis (PBC)Newcastle-upon-Tyne Hospitals Trustnephrotic syndromePBCcirrhosis
…Aim Ursodeoxycholic acid (UDCA) is the licensed 1st-line therapy for Primary Biliary Cholangiti…
seladelparursodeoxycholic acid (UDCA) who have an inadequate response to UDCASELUDCAprimary biliary cholangitis (PBC)PBCNCT03301506NCT04620733
…fness by baseline subgroups.Baseline was defined at the time of seladelpar initiation.n = the number of evaluable patients at each time po…
ursodeoxycholic acidUDCAportal hypertensionPrimary biliary cholangitis (PBC)gastroenterology departmentcoeliac diseaseautoimmune thyroiditisDiabetescirrhosis
…2, and 34(29.8%) F3-F4 (severe fibrosis). All patients received ursodeoxycholic acid (UDCA) at 13 mg/kg. Regarding prediction of severe fibrosis, th…
ELAFIBRANORSELADELPAROBETICHOLIC ACIDELFursodeoxycholic acidSELOCAUDCAprimary biliary cholangitisPBC
…% CI 23.7 – 50.3)) SELADELPAR (ARR = 40.9 (95% CI 28.1 – 53.8)) ELAFIBRANOR (ARR = 47.2 (95% CI 36.4 – 57.9)) ARR = 10.2 (-6.9 ; 27,3) p = …
Ursodeoxycholic acidUDCAPrimary biliary cholangitiscirrhosis
…stasis, persistent inflammation and, over time, fibrogenesis. 1 Ursodeoxycholic acid (UDCA) remains the first-line therapy and has significantly imp…
Seladelparseladelpar-treateddelparUDCAursodeoxycholic acidcirrhosis
…Seladelpar is a first-in-class delpar (selective PPAR-delta agonist) indic…
SeladelpardelparUDCAursodeoxycholic acidprimary biliary cholangitisPBC
…followed by the TB component (3M, −0.11; 1Y, −0.09; 2Y, −0.13). Seladelpar treatment for 3M, 1Y, and 2Y led to predicted changes in TFS wi…